首页> 美国卫生研究院文献>Stem Cells International >Occurring of In Vitro Functional Vasculogenic Pericytes from Human Circulating Early Endothelial Precursor Cell Culture
【2h】

Occurring of In Vitro Functional Vasculogenic Pericytes from Human Circulating Early Endothelial Precursor Cell Culture

机译:从人循环早期内皮前体细胞培养物中产生功能性血管生成周细胞

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Pericytes are periendothelial cells of the microcirculation which contribute to tissue homeostasis and hemostasis by regulating microvascular morphogenesis and stability. Because of their multipotential ex vivo differentiation capabilities, pericytes are becoming very interesting in regenerative medicine field. Several studies address this issue by attempting to isolate pericyte/mesenchymal-like cells from peripheral blood; however the origin of these cells and their culture conditions are still debated. Here we showed that early Endothelial Progenitor Cells (EPCs) expressing CD45+/CD146+/CD31+ can be a source of cells with pericyte/mesenchymal phenotype and function, identified as human Progenitor Perivascular Cells (hPPCs). We provided evidence that hPPCs have an immunophenotype consistent with Mesenchymal Stem Cells (MSCs) from human adipose tissue (hASCs) and fetal membranes of term placenta (FM-hMSCs). In addition, hPPCs can be subcultured and exhibit expression of pluripotent genes (OCT-4, KLF-4, and NANOG) as well as a remarkable vasculogenic potential. Our findings could be helpful to develop innovative cell-based therapies for future clinical applications with distinct therapeutic purposes.
机译:周细胞是微循环的内皮细胞,其通过调节微血管的形态和稳定性来促进组织的稳态和止血。由于其具有多能的离体分化能力,周细胞在再生医学领域变得非常有趣。一些研究试图通过从外周血中分离出周细胞/间充质样细胞来解决这个问题。然而,这些细胞的来源及其培养条件仍存在争议。在这里,我们表明表达CD45 + / CD146 + / CD31 +的早期内皮祖细胞(EPC)可能是具有周细胞/间充质表型和功能的细胞的来源,被鉴定为人类祖周血管细胞(hPPC)。我们提供的证据表明,hPPC具有与人脂肪组织(hASCs)和足月胎盘胎膜(FM-hMSCs)的间充质干细胞(MSCs)一致的免疫表型。此外,hPPC可以进行继代培养,并表现出多能基因(OCT-4,KLF-4和NANOG)的表达以及显着的血管生成潜力。我们的发现可能有助于开发创新的基于细胞的疗法,用于具有独特治疗目的的未来临床应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号